Literature DB >> 24562185

Method for obtaining primary ovarian cancer cells from solid specimens.

Lee J Pribyl1, Kathleen A Coughlin1, Thanasak Sueblinvong1, Kristin Shields2, Yoshie Iizuka3, Levi S Downs3, Rahel G Ghebre3, Martina Bazzaro4.   

Abstract

Reliable tools for investigating ovarian cancer initiation and progression are urgently needed. While the use of ovarian cancer cell lines remains a valuable tool for understanding ovarian cancer, their use has many limitations. These include the lack of heterogeneity and the plethora of genetic alterations associated with extended in vitro passaging. Here we describe a method that allows for rapid establishment of primary ovarian cancer cells form solid clinical specimens collected at the time of surgery. The method consists of subjecting clinical specimens to enzymatic digestion for 30 min. The isolated cell suspension is allowed to grow and can be used for downstream application including drug screening. The advantage of primary ovarian cancer cell lines over established ovarian cancer cell lines is that they are representative of the original specific clinical specimens they are derived from and can be derived from different sites whether primary or metastatic ovarian cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24562185      PMCID: PMC4116823          DOI: 10.3791/51581

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  10 in total

Review 1.  The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

Authors:  Cynthie Wong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-08       Impact factor: 4.292

2.  Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs).

Authors:  S W Tsao; S C Mok; E G Fey; J A Fletcher; T S Wan; E C Chew; M G Muto; R C Knapp; R S Berkowitz
Journal:  Exp Cell Res       Date:  1995-06       Impact factor: 3.905

3.  Ovarian Cancer Is an Imported Disease: Fact or Fiction?

Authors:  Elisabetta Kuhn; Robert J Kurman; Ie-Ming Shih
Journal:  Curr Obstet Gynecol Rep       Date:  2012-03

4.  In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.

Authors:  Molly Brewer; J Taylor Wharton; Jian Wang; Amanda McWatters; Nelly Auersperg; David Gershenson; Robert Bast; Changping Zou
Journal:  Gynecol Oncol       Date:  2005-08       Impact factor: 5.482

5.  Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients.

Authors:  Trevor G Shepherd; Brigitte L Thériault; Elizabeth J Campbell; Mark W Nachtigal
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

6.  Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes.

Authors:  N Auersperg; S L Maines-Bandiera; H G Dyck; P A Kruk
Journal:  Lab Invest       Date:  1994-10       Impact factor: 5.662

7.  In vivo-in vitro tumour cell lines: characteristics and limitations as models for human cancer.

Authors:  S Rockwell
Journal:  Br J Cancer Suppl       Date:  1980-04

Review 8.  Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.

Authors:  Robert J Kurman; Kala Visvanathan; Richard Roden; T C Wu; Ie-Ming Shih
Journal:  Am J Obstet Gynecol       Date:  2008-04       Impact factor: 8.661

9.  Early detection biomarkers for ovarian cancer.

Authors:  Sreeja Sarojini; Ayala Tamir; Heejin Lim; Shihong Li; Shifang Zhang; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Oncol       Date:  2012-12-23       Impact factor: 4.375

10.  Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors.

Authors:  Thanasak Sueblinvong; Rahel Ghebre; Yoshie Iizuka; Stefan E Pambuccian; Rachel Isaksson Vogel; Amy P N Skubitz; Martina Bazzaro
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  10 in total
  4 in total

1.  Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients.

Authors:  Amanda M Lulu; Kara L Cummings; Erin D Jeffery; Paisley T Myers; Dennis Underwood; Rachel M Lacy; Kimberly A Chianese-Bullock; Craig L Slingluff; Susan C Modesitt; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2021-08-19       Impact factor: 11.151

2.  Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.

Authors:  Kathleen Coughlin; Ravi Anchoori; Yoshie Iizuka; Joyce Meints; Lauren MacNeill; Rachel Isaksson Vogel; Robert Z Orlowski; Michael K Lee; Richard B S Roden; Martina Bazzaro
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

3.  Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer.

Authors:  Yimei Jin; Xin Xu; Xuemeng Wang; Henry Kuang; Michael Osterman; Shi Feng; Deqiang Han; Yu Wu; Mo Li; Hongyan Guo
Journal:  Oncotarget       Date:  2016-08-02

4.  Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients.

Authors:  Edyta Paradowska; Agnieszka Jabłońska; Mirosława Studzińska; Miłosz Wilczyński; Jacek R Wilczyński
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.